Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 2/20 | 0.79 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.79 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7802158 | 0.82 | MEN1 (0.53) | PLA2G1BATG4BKMT2AMEN1GAA | |
| SCHEMBL344132 | 0.82 | MEN1 (0.53) | PLA2G1BATG4BKMT2AMEN1LMNA | |
| SCHEMBL5878389 | 0.81 | ALOX12 (0.77) | PLA2G1BATG4BMAOBKMT2AMEN1 | |
| SCHEMBL20496874 | 0.78 | PLA2G1B (0.78) | PLA2G1BATG4BMAOBKMT2AMEN1 | |
| SCHEMBL7791780 | 0.78 | MEN1 (0.51) | PLA2G1BATG4BKMT2AMEN1LMNA | |
| SCHEMBL7800153 | 0.77 | PLA2G1B (0.46) | PLA2G1BATG4BKMT2AMEN1LMNA | |
| SCHEMBL11206964 | 0.76 | CDK1 (0.68) | KMT2AMEN1LMNAGAASMN1; SMN2 | |
| SCHEMBL12049602 | 0.76 | PLA2G1B (0.73) | PLA2G1BATG4B | |
| SCHEMBL7798360 | 0.76 | PLA2G1B (0.45) | PLA2G1BATG4BKMT2ALMNA | |
| SCHEMBL12049612 | 0.76 | PLA2G1B (0.61) | PLA2G1BATG4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013074320-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| US-20120083508-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120083508-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN, INC. (US) | 2012-04-05 | — | — | US | disclosed |
| US-7754768-B2 | Methods and compositions for modulating alpha adrenergic receptor activity | ALLERGAN, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754768-B2 | Methods and compositions for modulating alpha adrenergic receptor activity | ALLERGAN, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20100016355-A1 | ALPHA-2B ADRENERGIC RECEPTOR AGONIST AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR COMPOSITIONS FOR TREATING CHRONIC PAIN | GIL DANIEL W | 2010-01-21 | — | — | US | disclosed |
| US-20100016355-A1 | ALPHA-2B ADRENERGIC RECEPTOR AGONIST AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR COMPOSITIONS FOR TREATING CHRONIC PAIN | GIL DANIEL W | 2010-01-21 | — | — | US | disclosed |
| WO-2008079720-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATNG CHRONIC PAIN | ALLERGAN, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008079728-A2 | ALPHA-2B ADRENERGIC RECEPTOR AGONIST AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153825-A1 | ALPHA-2B RECEPTOR AGONIST AND 5HT4 SEROTONIN RECEPTOR COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | ALLERGAN INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153825-A1 | ALPHA-2B RECEPTOR AGONIST AND 5HT4 SEROTONIN RECEPTOR COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | ALLERGAN INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080153881-A1 | ALPHA-2B RECEPTOR AGONIST AND ACID REDUCER COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | ALLERGAN, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080132576-A1 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | ALLERGAN, INC. | 2008-06-05 | — | — | US | disclosed |
| US-20080132576-A1 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | ALLERGAN, INC. | 2008-06-05 | — | — | US | disclosed |
| US-7335803-B2 | Methods and compositions for modulating alpha adrenergic receptor activity | ALLERGAN, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335803-B2 | Methods and compositions for modulating alpha adrenergic receptor activity | ALLERGAN, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| WO-2007041435-A1 | METHODS FOR TREATING PAIN AND HYPERHIDROSIS | ALLERGAN, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070048335-A1 | Methods for treating pain and hyperhidrosis | ALLERGAN, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070048335-A1 | Methods for treating pain and hyperhidrosis | ALLERGAN, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| WO-2003035178-A1 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016355-A1 | ALPHA-2B ADRENERGIC RECEPTOR AGONIST AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR COMPOSITIONS FOR TREATING CHRONIC PAIN | ADRA2B, ADRA1B, ADRB1 | PLA2G1B 497/4885ATG4B 2611/4885MAOB 53/4885 |
| US-20080153881-A1 | ALPHA-2B RECEPTOR AGONIST AND ACID REDUCER COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | ADRA2B, GPBAR1, MLNR | PLA2G1B 390/4885ATG4B 1402/4885MAOB 402/4885 |
| US-20070048335-A1 | Methods for treating pain and hyperhidrosis | ADRA2A, OPRL1, OPRK1 | PLA2G1B 421/4885ATG4B 4049/4885MAOB 957/4885 |
| US-20120083508-A1 | ALPHA-2B RECEPTOR AGONIST AND ANTICONVULSANT COMPOSITIONS FOR TREATING CHRONIC PAIN | CNR2, OPRL1, OPRD1 | PLA2G1B 337/4885ATG4B 2312/4885MAOB 689/4885 |
| US-20080132576-A1 | METHODS AND COMPOSITIONS FOR MODULATING ALPHA ADRENERGIC RECEPTOR ACTIVITY | ADRB2, ADRA2A, ADRB1 | PLA2G1B 236/4885ATG4B 3909/4885MAOB 747/4885 |
| US-20080153825-A1 | ALPHA-2B RECEPTOR AGONIST AND 5HT4 SEROTONIN RECEPTOR COMPOSITIONS FOR TREATING GASTROINTESTINAL MOTILITY DISORDERS | HTR2B, HTR4, HTR3B | PLA2G1B 354/4885ATG4B 472/4885MAOB 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.